I really enjoyed speaking with Pharmaceutical Executive about the recent FDA approval of Bristol Myers Squibb’s #schizophrenia drug Cobenfy (formerly KarXT). This approval is exciting as it opens the door to further innovations in the space. With our program TerXT, a combination of novel prodrugs of xanomeline and trospium (the two active compounds in Cobenfy), we are pursuing an accelerated 505(b)(2) development pathway with the goal of delivering once-daily form of the drug as well as a multi-month long-acting injectable form.
Terran Biosciences
生物技术研究
Miami，FL 2,170 位关注者
Transforming the lives of patients with neurological and psychiatric illnesses
关于我们
Terran is developing a broad portfolio of transformative therapeutics and technologies to change the lives of patients with neurological and psychiatric diseases. Please contact us to learn more.
- 网站
-
https://terranbiosciences.com/
Terran Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Miami，FL
- 类型
- 私人持股
地点
-
主要
获取路线
US，FL，Miami
Terran Biosciences员工
动态
-
I’m excited to be speaking at the CNS Summit in Boston next Tuesday Nov 12th about our lead #schizophrenia therapeutic TerXT, a prodrug form of xanomeline and trospium, the active compounds in the recently approved KarXT (now Cobenfy). TerXT is designed to enable a once-daily oral form of xanomeline and trospium as well as a long-acting injectable form with a multi-month duration.
Watch this incredible lineup during the Neuroscience Spotlight Sessions at #CNSSummit2024 Harry Tracy | Atul Mahableshwarkar | Johannes Streffer | Kevin Craig | Ryan Field | Thomas Thompson | Gayle Wittenberg, Ph.D. | Corey Reuteman-Fowler, Ph.D. | Anzar Abbas | Spyros Papapetropoulos MD, PhD | Alessio Travaglia | Steve Gardner | Sam Clark, MD PhD | Shane Hegarty | David Pattison, CPA | Wen Luo
-
-
The Terran team is thrilled to have been selected as a Fierce Life Science Innovation Award finalist for our FDA-approved NM-101 software technology to aid in the evaluation of #ParkinsonsDisease and other neuropsychiatric conditions. We are honored to be recognized alongside the top industry pioneers in the medical device space. #FierceLifeSciencesAwards #FierceInnovationAwards
?? Congratulations to the Fierce Life Sciences Innovation Awards Finalists! ?? These remarkable innovators are leading the charge in biotech, drug development, digital health, and more. Their groundbreaking work is setting new standards in the industry, and we can't reveal the winners on December 2nd. Check out the full list of trailblazing finalists here: https://shorturl.at/yBecz Join our mailing list to stay updated on the winners: https://shorturl.at/E1PAg #LifeSciences #Innovation #Biotech #Healthcare #DigitalHealth #Pharma #FierceInnovationAwards #FierceLifeSciences #FierceLifeSciencesInnovationAwards
-
I enjoyed speaking with Abby Proch from Clinical Leader Life Science Connect about our strategy for the rapid development of TerXT for patients with schizophrenia using FDA’s accelerated 505(b)(2) regulatory pathway to reference data from the recently-approved KarXT (Cobenfy).
?? ? ?? The 505(b)(2) pathway enables drugs to more quickly pass through the clinical stage and reach patients. The decision to do so often involves piggybacking on approved meds for a quicker entrance to market. In this Q&A, Sam Clark, MD PhD explains how Terran Biosciences is tagging on to the recent FDA approval of Bristol Meyer Squibb’s Cobenfy (formerly Karuna Therapeutics' KarXT). #clinicaltrials #clinicalresearch
How One Biotech Is Using FDA 505(b)(2) To Get Drugs To Patients Quicker And Cheaper
clinicalleader.com
-
Terran's CEO Sam Clark, MD PhD recently moderated an HCPLive panel alongside key opinion leaders Andrew Cutler and Rishi Kakar (lead investigator on the KarXT trials), to discuss the recent FDA approval of KarXT (Cobenfy) for #schizophrenia, and what this could mean for patients and future therapeutics.
?? New Special Report! ?? We’re excited to present a special 5-part series on Embracing New Therapies in Schizophrenia Management, with insights from leading subject matter experts Rishi Kakar, MD, of Segal Trials, Andrew Cutler, MD, Neuroscience Education Institute, and moderator Sam Clark, MD PhD, of Terran Biosciences. In this series, we dive deep into the groundbreaking FDA-approved schizophrenia treatment, xanomeline and trospium chloride capsules (Cobenfiy; Bristol Myers Squibb), and its novel mechanism of action targeting muscarinic receptors instead of traditional dopamine pathways. The series highlights key clinical trial data, symptom management, and how these new therapies could revolutionize treatment for patients who haven't fully responded to traditional antipsychotics. Watch and learn how these advancements may shape the future of schizophrenia care, improve patient outcomes, and address unmet needs in managing this complex condition. In the segment below, the experts discuss the application of clinical trial data to real-world settings. Use the link for the full series! https://lnkd.in/eDvyx_9S #Schizophrenia #Neuropsychiatry #MentalHealth #Psychiatry
-
As a global leader in psychedelic manufacturing and supply, Terran is excited to provide psilocybin, LSD, and DMT, to Gitte Moos Knudsen's lab at the NRU at Rigshospitalet Copenhagen University Hospital to support their groundbreaking research in psychiatry and neurology. These are some of the many psychedelic compounds Terran is providing to researchers and clinics.
-
On the heels of the FDA’s decision to approve the groundbreaking schizophrenia drug KarXT (Cobenfy), Terran’s CEO Sam Clark, MD PhD connected with Kelly Bilodeau at PharmaVoice alongside Karuna Therapeutics founder Andrew Miller for a discussion of this exciting space and how a KarXT approval opens the door for future innovation and novel therapies like TerXT.
Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades
pharmavoice.com
-
Terran’s CEO Sam Clark, MD PhD shared his thoughts on the FDA’s recent approval of KarXT (Cobenfy) for #schizophrenia in this article by Melissa Rudy at Fox News Media alongside commentary by Bristol Myers Squibb CEO Chris Boerner. Dr. Clark discusses what this breakthrough means for patients, and what other innovations could quickly follow.
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
foxnews.com
-
Today at 10:00am ET, Terran’s founder and CEO, Sam Clark, MD PhD will be presenting on our unique prodrug approach to create novel therapeutics like TerXT for the treatment of #schizophrenia. Register for the webinar below:
The latest advancements driving neuroscience drug discovery research In this webinar, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, MD PhD, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. ? Dr Klein shares how Dewpoint applies insights into the subcellular organisation of biochemical processes into membrane-less compartments to discover novel drug targets and revolutionary drugs for diseases with high unmet need, including amyotrophic lateral sclerosis (ALS) and Rett Syndrome. Dr Clark’s presentation will cover the intersection of medicinal chemistry and drug discovery as well as how this can help address the unmet medical need for new therapeutics in the neuropsych space. Professor Roberts will explore how an integrated in vitro seizure liability assay can benefit drug discovery for companies exploring central nervous system diseases. What you will learn: ? Where are the breakthroughs in neuroscience research? ? How are advanced technologies proving beneficial to drug discovery and development? ? How is the current unmet need within drug discovery and development for central nervous system (CNS) disorders providing opportunity? A Q&A session follows the webinar presentations. Mon, Sep 30, 2024 3:00 PM - 4:00 PM BST Register today! https://lnkd.in/em3QDi5n #Neuroscience #Drugdiscovery #DrugDevelopment
-
-
Late last night the FDA announced they had approved the new #schizophrenia drug Cobenfy (formerly KarXT), a huge win for patients who had been waiting many years for a new breakthrough. Terran CEO Sam Clark, MD PhD spoke with Chelsie Derman at HCPLive and shared his thoughts on what this means for the neurospcyhiatry space and how this paves the way for future innovation.
?? BREAKING NEWS ?? The US FDA has announced the approval xanomeline and trospium chloride capsules (Cobenfy), for schizophrenia. The approval, which was awarded to Bristol Myers Squibb, makes Cobenfy the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors https://lnkd.in/gvgU-qee #Schizophrenia #Psychiatry
-